Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs KeyCorp (KEY) Price & Performance

Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs KeyCorp — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while KeyCorp trades at $22.7 (market cap $24.31B). The key difference: KeyCorp is far larger — about 509.1× Cassava Sciences Inc's market cap, and KeyCorp pays a 3.62% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAKEY
Market Cap
$47.75M$24.31B
Sector
HealthFinancials
52-Week High
$4.64$23.99
52-Week Low
$0.87$16.78
Enterprise Value
-$34.93M
Dividend Yield
3.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

KeyCorp

KeyCorp (KEY) trades at $22.73, up 0.31% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.41. Recent Q2 2026 earnings beat estimates with EPS of $0.44, driven by net interest income growth and fee expansion. The acquisition of Clearwater UK bolsters its investment banking presence, while a 3.6% dividend yield adds income appeal.

Outlook is positive with earnings momentum and strategic acquisitions supporting growth, but risks include interest rate sensitivity and competitive pressures. Wall Street sentiment is bullish with 61% buy ratings, though net cash flow volatility and modest ROE of 2.72% warrant caution for value-focused investors.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About KeyCorp

With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.

Read more on KEY